Adrenomedullin Peptides

Handbook of Biologically Active Peptides

Volumn , Issue , 2013, Pages 1361-1368

  Kato, Johji ^a   Kitamura, Kazuo ^b  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884952175     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-385095-9.00185-8     Document Type: Chapter

References (35)

1. Caron K., Hagaman J., Nishikimi T., Kim H.S., Smithies O. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci U S A 2007, 104:3420-3425.
2. Chao J., Chao L. The role of adrenomedullin in cardiovascular and renal function. Drug News Perspect 2002, 15:511-518.
3. Eto T., Kitamura K., Kato J. Biological and clinical roles of adrenomedullin in circulation control and cardiovascular diseases. Clin Exp Pharmacol Physiol 1999, 26:371-380.
4. Fritz-Six K.L., Dunworth W.P., Li M., Caron K.M. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008, 118:40-50.
5. Hong Y., Hay D.L., Quirion R., Poyner D.R. The pharmacology of adrenomedullin 2/intermedin. Br J Pharmacol 2012, 166:110-120.
6. Iimuro S., Shindo T., Moriyama N., Amaki T., Niu P., Takeda N., et al. Angiogenic effects of adrenomedullin in ischemia and tumor growth. Circ Res 2004, 95:415-423.
7. Kataoka Y., Miyazaki S., Yasuda S., Nagaya N., Noguchi T., Yamada N., et al. The first clinical pilot study of intravenous adrenomedullin administration in patients with acute myocardial infarction. J Cardiovasc Pharmacol 2010, 56:413-419.
8. Kato J., Kitamura K., Eto T. Plasma adrenomedullin level and development of hypertension. J Hum Hypertens 2006, 20:566-570.
9. Kato J., Kuwasako K., Kitamura K. Adrenomedullin in hypertension and obesity. Curr Hypertens Rev 2011, 4:257-267.
10. Kato J., Tsuruda T., Kita T., Kitamura K., Eto T. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005, 25:2480-2487.
11. Kato J., Tsuruda T., Kitamura K., Eto T. Adrenomedullin: a possible autocrine or paracrine hormone in the cardiac ventricles. Hypertens Res 2003, (Suppl. 26):S113-S119.
12. Kitamura K., Kangawa K., Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Technol 2002, 57:3-13.
13. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560.
14. Kitamura K., Kato J., Kawamoto M., Tanaka M., Chino N., Kangawa K., et al. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem Biophys Res Commun 1998, 244:551-555.
15. Kuwasako K., Kitamura K., Nagata S., Hikosaka T., Takei Y., Kato J. Shared and separate functions of the RAMP-based adrenomedullin receptors. Peptides 2011, 32:1540-1550.
16. Leskinen H., Rauma-Pinola T., Szokodi I., Kerkelä R., Pikkarainen S., Uusimaa P., et al. Adaptive or maladaptive response to adenoviral adrenomedullin gene transfer is context-dependent in the heart. J Gene Med 2008, 10:867-877.
17. Li Y., Jiang C., Wang X., Zhang Y., Shibahara S., Takahashi K. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides 2007, 28:1129-1143.
18. Liang L., Tam C.W., Pozsgai G., Siow R., Clark N., Keeble J., et al. Protection of angiotensin II-induced vascular hypertrophy in vascular smooth muscle-targeted receptor activity-modifying protein 2 transgenic mice. Hypertension 2009, 54:1254-1261.
19. Maisel A., Mueller C., Nowak R., Peacock W.F., Landsberg J.W., Ponikowski P., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
20. Maki T., Ihara M., Fujita Y., Nambu T., Miyashita K., Yamada M., et al. Angiogenic and vasoprotective effects of adrenomedullin on prevention of cognitive decline after chronic cerebral hypoperfusion in mice. Stroke 2011, 42:1122-1128.
21. Martínez A. A new family of angiogenic factors. Cancer Lett 2006, 236:157-163.
22. McLatchie L.M., Fraser N.J., Main M.J., Wise A., Brown J., Thompson N., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393(6683):333-339.
23. Morales M.A., Maltinti M., Piacenti M., Turchi S., Giannessi D., Del Ry S. Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy. Pacing Clin Electrophysiol 2010, 33:865-872.
24. Murakami S., Kimura H., Kangawa K., Nagaya N. Physiological significance and therapeutic potential of adrenomedullin in pulmonary hypertension. Cardiovasc Hematol Disord Drug Targets 2006, 6:125-132.
25. Nagaya N., Mori H., Murakami S., Kangawa K., Kitamura S. Adrenomedullin: angiogenesis and gene therapy. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1432-R1437.
26. Nishida H., Horio T., Suzuki Y., Iwashima Y., Kamide K., Kangawa K., et al. Plasma adrenomedullin as an independent predictor of future cardiovascular events in high-risk patients: comparison with C-reactive protein and adiponectin. Peptides 2008, 29:599-605.
27. Nishikimi T. Adrenomedullin in the kidney-renal physiological and pathophysiological roles. Curr Med Chem 2007, 14:1689-1699.
28. Nishikimi T., Matsuoka H. Cardiac adrenomedullin: its role in cardiac hypertrophy and heart failure. Curr Med Chem Cardiovasc Hematol Agents 2005, 3:231-242.
29. Niu P., Shindo T., Iwata H., Iimuro S., Takeda N., Zhang Y., et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation 2004, 109:1789-1794.
30. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001, 37:1781-1787.
31. Roh J., Chang C.L., Bhalla A., Klein C., Hsu S.Y. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem 2004, 279:7264-7274.
32. Shimosawa T., Fujita T. Adrenomedullin as a potent antioxidative and antiatherosclerotic substance. Drug News Perspect 2005, 18:185-189.
33. Smith R.S., Gao L., Bledsoe G., Chao L., Chao J. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol 2009, 297:H1040-H1047.
34. Takei Y., Inoue K., Ogoshi M., Kawahara T., Bannai H., Miyano S. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator. FEBS Lett 2004, 556:53-58.
35. von Haehling S., Filippatos G.S., Papassotiriou J., Cicoira M., Jankowska E.A., Doehner W., et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010, 12:484-491.